Resources

Our Care Team

News

Research 无症状阶段精准评估早期肝硬化风险觅瑞联手国立癌症中心推新检测本地生物科技公司觅瑞与新加坡国立癌症中心联合宣布，正式推出无创血液微核糖核酸（miRNA）检测工具CIRRHOClear. 这项技术能在无症状阶段精准评估受检者的早期肝硬化风险，帮助高危人群争取及早干预与疾病管理的黄金时间.

19 Oct 2026 | Lianhe Zaobao Read Story

Research Mirxes and NCCS Launch CIRRHOClear™: A Breakthrough Blood Test for Early Liver Cirrhosis Risk Stratification CIRRHOClear™ leverages intellectual property jointly owned by Mirxes and NCCS, developed from the landmark liver study, ELEGANCE . Licensed to Mirxes for use in its proprietary microRNA (miRNA) panel technology, it identifies individuals at risk of developing liver cirrhosis before symptoms appear, enabling proactive early intervention and disease management.

16 Oct 2026 Read Story

Announcements Changi General Hospital first in Singapore to earn top international age-friendly care recognition Individualising treatment, deprescribing, and recognising delirium early amongst initiatives that earn CGH recognition as a leader in care for older adults

14 Oct 2026 Read Story

View All News